FDA won't OK prescription weight-loss drug Qnexa

The FDA has asked the drug company, Vivus, to provide data about whether Qnexa can cause birth defects and to quantify what that risk might be. Vivus expects to be able to address the concerns.The Food and Drug Administration has declined to approve the prescription weight-loss drug Qnexa, but the company that developed it said it remains hopeful that the medication will reach the marketplace eventually.

Read the whole article on LA Times - Health

More from LA Times - Health